No Data
Biotech 2024 Third Quarter Report
bio-thera solutions (688177.SH) releases performance for the first three quarters, with a net loss of 0.365 billion yuan
Bio-Thera Solutions (688177.SH) released the report for the first three quarters of 2024. During the reporting period, the company achieved revenue of 5...
Bio-Thera Solutions (688177.SH): a net loss of 0.365 billion yuan in the first three quarters.
GeLongHui October 29 | Bio-Thera Solutions (688177.SH) announced that in the first three quarters of 2024, revenue reached 0.581 billion yuan, a year-on-year increase of 26.11%; net income attributable to shareholders of the listed company was -0.365 billion yuan, with a basic earnings per share of -0.88 yuan.
Bocom Intl: Guangzhou launches first batch of innovative drugs and medical devices catalog, focusing on innovation and consumer properties as symbols.
Following the introduction of policies encouraging the innovation of pharmaceuticals, the latest innovative drug and medical device product catalog released by Guangzhou will further provide full-chain, all-field support to the high-quality development of the biomedical industry.
Star Evening News | Minmetals New Energy, Bio-Thera Solutions, and 6 other companies announced their shareholding reduction plans. Vertical and horizontal shares receive an administrative supervision decision letter from Sichuan Securities Regulatory Bure
1. Guangdong may introduce demonstration clauses for technology insurance such as biomedical and integrated circuits; 2. Shenzhen: Accelerating the establishment of a multi-billion-dollar Shenzhen semiconductor and integrated circuit industry investment fund; 3. The Shanghai Stock Exchange terminates the listing and issuance review of Feixiang Technology on the Star Market.
Bio-Thera Solutions Enters Up to $110 Million Licensing Deal With Gedeon Richter
Bio-Thera Solutions, Ltd.'s (SHSE:688177) 26% Price Boost Is Out Of Tune With RevenuesNo Data
No Data
